Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
暂无分享,去创建一个
Paul G Shekelle | Yee-Wei Lim | Aneesa Motala | Sydne J Newberry | P. Shekelle | Y. Lim | C. Crandall | W. Gellad | A. Diamant | A. Motala | S. Newberry | Walid F Gellad | M. Booth | Carolyn J Crandall | Allison Diamant | Marika J Booth
[1] M. Lee,et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis , 2014, Osteoporosis International.
[2] H. Tsuchiya,et al. Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy , 2012, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[3] Hang Lee,et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.
[4] Jacques P. Brown,et al. The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension , 2013, The Journal of clinical endocrinology and metabolism.
[5] B. Abrahamsen. Bisphosphonate adverse effects, lessons from large databases , 2010, Current opinion in rheumatology.
[6] Dennis M. Black,et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy , 2002 .
[7] H. Harputluoglu,et al. Zoledronic acid and atrial fibrillation in cancer patients , 2011, Supportive Care in Cancer.
[8] J. Fowler,et al. Association of low-energy femoral shaft fractures and bisphosphonate use. , 2012, Orthopedics.
[9] A. Garg,et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. , 2012, Kidney international.
[10] C. Moran,et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. , 2012, The Journal of bone and joint surgery. British volume.
[11] T. Kotsimbos,et al. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF) , 2009, Clinical endocrinology.
[12] G. Mazzaglia,et al. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures , 2013, Osteoporosis International.
[13] S. Schneeweiss,et al. Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[15] C. Lawton. Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer , 2011 .
[16] A. García-García,et al. Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain , 2012, Medicina oral, patologia oral y cirugia bucal.
[17] M. Etminan,et al. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study , 2012, Canadian Medical Association Journal.
[18] R. Eastell,et al. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study , 2012, Osteoporosis International.
[19] H. El‐Serag,et al. Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus , 2010, Digestive Diseases and Sciences.
[20] Susanne Hempel,et al. A Pilot Study Using Machine Learning and Domain Knowledge to Facilitate Comparative Effectiveness Review Updating , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[21] K. Toulis,et al. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab , 2010, Osteoporosis International.
[22] S. Cummings,et al. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[24] C. Shin,et al. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry , 2013, Osteoporosis International.
[25] J. Goodwin,et al. Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. , 2011, The Annals of pharmacotherapy.
[26] S. Fitzpatrick,et al. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. , 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[27] W. Chung,et al. Characteristics of Bisphosphonate-Related Osteonecrosis of the Jaw After Kidney Transplantation , 2012, The Journal of craniofacial surgery.
[28] M. Swiontkowski,et al. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft , 2012 .
[29] A. Migliore,et al. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. , 2013, European review for medical and pharmacological sciences.
[30] S. Cummings,et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] Jacques P. Brown,et al. Bisphosphonate Associated Osteonecrosis of the Jaw , 2009, The Journal of Rheumatology.
[32] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[33] P. Geusens,et al. Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[34] F. Hsiao,et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. , 2011, Clinical therapeutics.
[35] Y. Kitagawa,et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. , 2011, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[36] P. Keogh,et al. Subtrochanteric stress fractures in patients on oral bisphosphonate therapy: an emerging problem. , 2011, Acta orthopaedica Belgica.
[37] S. Ogino,et al. A prospective study of bisphosphonate use and risk of colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Andrici,et al. Meta‐analysis: oral bisphosphonates and the risk of oesophageal cancer , 2012, Alimentary pharmacology & therapeutics.
[39] K. Brixen,et al. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[40] C. Abnet,et al. Exposure to oral bisphosphonates and risk of cancer , 2012, International journal of cancer.
[41] D. Juurlink,et al. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis , 2014, Osteoporosis International.
[42] L. Shulman. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure , 2010 .
[43] Gabriela Czanner,et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BMJ : British Medical Journal.
[44] E. Andrews,et al. The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] K. Rothman,et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis , 2012, Pharmacoepidemiology and drug safety.
[46] Jacques P. Brown,et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.
[47] Marcea Whitaker,et al. Bisphosphonates for osteoporosis--where do we go from here? , 2012, The New England journal of medicine.
[48] C. Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Editorial comment , 2009 .
[49] Toshitaka Nakamura,et al. Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis , 2013, Calcified Tissue International.
[50] Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone , 2011, ISRN rheumatology.
[51] G. Hooper,et al. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review , 2012, ANZ journal of surgery.
[52] David Moher,et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews , 2007, BMC medical research methodology.
[53] Martha Timmer,et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis , 2007, Annals of Internal Medicine.
[54] H. Sørensen,et al. Oral bisphosphonates and risk of ischemic stroke: a case–control study , 2011, Osteoporosis International.
[55] G. Ning,et al. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies , 2012, Osteoporosis International.
[56] S. Silverman,et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[57] G. Mast,et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. , 2012, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[58] P. Vestergaard,et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene , 2011, Osteoporosis International.
[59] Klaus Klaushofer,et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[60] M. Seibel,et al. Atypical femoral fractures and bisphosphonate use. , 2010, The New England journal of medicine.
[61] T. Brown,et al. Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294)) , 2011 .
[62] B. Clarke. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur , 2011 .
[63] K. Beattie,et al. Atypical Femoral Fractures in Patients Taking Longterm Alendronate , 2011, The Journal of Rheumatology.
[64] J. Hartle,et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[65] E. Chamizo Carmona,et al. Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis. , 2013, Reumatologia clinica.
[66] R. Goeree,et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women , 2011, BMC musculoskeletal disorders.
[67] O. Almășan,et al. Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases. , 2011, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[68] J. Babb,et al. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. , 2012, AJR. American journal of roentgenology.
[69] J. S. San Martin,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.
[70] P. Vestergaard. Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis , 2011, Calcified Tissue International.
[71] E. Barrett-Connor,et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials , 2011, Osteoporosis International.
[72] G. D. Vedova,et al. Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case–control study , 2014, BMC Gastroenterology.
[73] M. Hongo,et al. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series , 2012, Journal of Bone and Mineral Metabolism.
[74] J. Hippisley-Cox,et al. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data , 2013, BMJ.
[75] T. Tomomitsu,et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study , 2013, Osteoporosis International.
[76] M. Fukunaga,et al. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis , 2013, Calcified Tissue International.
[77] F. Hsiao,et al. Alendronate and Risk of Esophageal Cancer: A Nationwide Population‐Based Study in Taiwan , 2011, Journal of the American Geriatrics Society.
[78] T. Bhattacharyya,et al. Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996–2007 , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[79] S. Das De,et al. Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy. , 2011, Injury.
[80] Steven Boonen,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[81] T. Perneger,et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. , 2012, Archives of internal medicine.
[82] Peter C Austin,et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. , 2011, JAMA.
[83] P. Choong,et al. Burden of bisphosphonate‐associated femoral fractures , 2013, ANZ journal of surgery.
[84] Thomas D Brown,et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[85] S. Boonen,et al. Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial , 2011, Calcified Tissue International.
[86] J. Lee,et al. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis , 2011, Osteoporosis International.
[87] M. Chao,et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women , 2013, Pakistan journal of medical sciences.
[88] Douglas K Owens,et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. , 2010, Journal of clinical epidemiology.
[89] J. Jansen,et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. , 2011, Seminars in arthritis and rheumatism.
[90] J. Hippisley-Cox,et al. Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case–control studies using two primary-care databases , 2013, British Journal of Cancer.
[91] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[92] M. Yavropoulou,et al. Low‐energy fractures of the humeral shaft and bisphosphonate use , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[93] S. White. Romosozumab in postmenopausal women with low bone mineral density , 2014 .
[94] F. Sung,et al. A Higher Dosage of Oral Alendronate Will Increase the Subsequent Cancer Risk of Osteoporosis Patients in Taiwan: A Population-Based Cohort Study , 2012, PLoS ONE.
[95] D. Solomon,et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[96] Aitao Guo,et al. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women , 2013, The Journal of international medical research.
[97] D. Matlock,et al. "Due" for a scan: examining the utility of monitoring densitometry. , 2013, JAMA internal medicine.
[98] J. Dungan. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur , 2011 .
[99] Aliya A. Khan. Bisphosphonate-associated osteonecrosis of the jaw. , 2008, Canadian family physician Medecin de famille canadien.
[100] D. Kiel,et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. , 2013, JAMA.
[101] Y. Kumagai,et al. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. , 2011, Bone.
[102] J. Lo,et al. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. , 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[103] T. Mücke,et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. , 2011, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[104] W. Ward,et al. Femoral Stress Fractures Associated With Long-term Bisphosphonate Treatment , 2012, Clinical orthopaedics and related research.
[105] Cyrus R. Mehta,et al. Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2×2 Contingency Tables , 1985 .
[106] D. Ransohoff,et al. Bone-density testing interval and transition to osteoporosis in older women. , 2012, The New England journal of medicine.
[107] B. Ettinger,et al. Clinical correlates of atypical femoral fracture. , 2012, Bone.
[108] A. Giusti,et al. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. , 2010, Bone.
[109] B. Abrahamsen,et al. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases , 2012, Osteoporosis International.
[110] S. Cummings,et al. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial , 2005, Osteoporosis International.
[111] Tzeng-Ji Chen,et al. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[112] Tianjing Li,et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.
[113] Fran Harris,et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.
[114] Kay Dickersin,et al. Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.
[115] Joydeep Ghosh,et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. , 2013, Chest.
[116] Daniel H Solomon,et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis , 2010, Arthritis research & therapy.
[117] S. Saussez,et al. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases , 2010, Journal of Cancer Research and Clinical Oncology.
[118] J. Reginster,et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. , 2012, The New England journal of medicine.
[119] P. Delmas,et al. Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate , 2010, Calcified Tissue International.
[120] Herng‐Ching Lin,et al. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke , 2012, Osteoporosis International.
[121] Jacques P. Brown,et al. Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[122] M. Swiontkowski. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis , 2011 .
[123] D. Mellström,et al. Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.
[124] S. Schneeweiss,et al. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults , 2009, Osteoporosis International.
[125] T. Sone,et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. , 2012, The Journal of clinical endocrinology and metabolism.
[126] Á. Ramos-Macías,et al. Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws , 2012, Medicina oral, patologia oral y cirugia bucal.
[127] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[128] Sonal Singh,et al. Bisphosphonates and Atrial Fibrillation , 2009, Drug safety.
[129] S. Cummings,et al. Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON‐PFT, and FREEDOM trials , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[130] R. Marcos,et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies. , 2013 .
[131] S. Cummings,et al. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? , 2012, The New England journal of medicine.
[132] U. P. S. T. Force,et al. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement , 2011, Annals of Internal Medicine.
[133] G. Lyritis,et al. Simultaneous bilateral atypical femoral fractures after alendronate therapy. , 2012, Journal of musculoskeletal & neuronal interactions.
[134] I. Reid,et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. , 2008, Journal of the American Dental Association.
[135] J. Avorn,et al. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges , 2012, Osteoporosis International.
[136] J. Schneider,et al. Atypical femur fractures: 81 individual personal histories. , 2012, The Journal of clinical endocrinology and metabolism.
[137] P. Vescovi,et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. , 2011, Oral oncology.
[138] P. Delmas,et al. Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide‐Treated Postmenopausal Women With Osteoporosis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[139] S. Belknap,et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. , 2013, The Journal of bone and joint surgery. American volume.
[140] P. Seed,et al. More data using same database , 2010, BMJ : British Medical Journal.
[141] L. Vilá,et al. Atypical subtrochanteric fractures associated with long-term use of bisphosphonates. , 2011, Puerto Rico health sciences journal.
[142] D. Reid,et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. , 2010, Journal of the American Dental Association.
[143] N. Freemantle,et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis , 2012, Osteoporosis International.